Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism, under its Accelerated Approval pathway, for potential therapeutics to be approved based in part on their ability to reduce brain amyloid. Through this pathway, two monoclonal anti-amyloid antibodies, aducanumab and lecanemab, have been approved for clinical use. More recently, another amyloid-lowering antibody, donanemab, generated a statistically significant outcome in a phase 3 clinical trial and will shortly come under FDA review. While these monoclonal antibodies are not yet routinely used in clinical practice, the series of recent positive clinical trials has fostered enthusiasm amongst some AD experts. Here, we discuss three key limitations regarding recent anti-amyloid clinical trials: (1) there is little to no evidence that amyloid reduction correlates with clinical outcome, (2) the reported efficacy of anti-amyloid therapies may be partly, or wholly, explained by functional unblinding, and (3) donanemab in its phase 3 trial had no effect on tau burden, the pathological hallmark more closely related to cognition. Taken together, these observations call into question the efficacy of anti-amyloid therapies.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Goodhart's Law Applies to NLP's Explanation Benchmarks
Despite the rising popularity of saliency-based explanations, the research community remains at an impasse, facing doubts concerning their purpose, efficacy, and tendency to contradict each other. Seeking to unite the co…
ClaimDB: A Fact Verification Benchmark over Large Structured Data
Real-world fact-checking often involves verifying claims grounded in structured data at scale. Despite substantial progress in fact-verification benchmarks, this setting remains largely underexplored. In this work, we in…
Fact VerificationRevisiting Overthinking in Long Chain-of-Thought from the Perspective of Self-Doubt
Reasoning Large Language Models (RLLMs) have demonstrated impressive performance on complex tasks, largely due to the adoption of Long Chain-of-Thought (Long CoT) reasoning. However, they often exhibit overthinking -- pe…
Mathematical ReasoningA Second Pandemic? Analysis of Fake News About COVID-19 Vaccines in Qatar
While COVID-19 vaccines are finally becoming widely available, a second pandemic that revolves around the circulation of anti-vaxxer fake news may hinder efforts to recover from the first one. With this in mind, we perfo…
Artificial Intolerance: Stigmatizing Language in Clinical Documentation Skews Large Language Model Decision-Making
Large Language Models (LLMs) are increasingly deployed in high-stakes domains such as clinical decision support and medical documentation. However, the robustness of these models against subtle linguistic variations, spe…